PE Can Narrow Health Inequality Gap by Funding Drug Development
The economics of drug development can often limit the development and dissemination of treatments in society – but is the increasing involvement of private equity changing this narrative?
Traditionally, venture capitalists come in at the beginning of the drug development process, writing moderate-sized cheques to fund the smaller trials in phases one and two. But when they get to the pivotal phase three trials, these trials typically require large investment – and many treatments will not get over the line if the money has
Check out more via Private And Equity News